



Breaking News

Kingchem Life Science Announces Major Expansion of Wisconsin CDMO Manufacturing Campus

Kingchem Life Science, a U.S.-founded and controlled contract development and manufacturing organization (CDMO) with a global footprint specializing in complex small-molecule chemistry, has initiated a significant expansion of its Wisconsin manufacturing campus to support growing demand for advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs).


The expansion will enhance the site's process development and cGMP manufacturing capabilities while significantly expanding analytical R&D laboratory space, QA/QC infrastructure, and overall production capacity supporting early- and late-stage pharmaceutical programs.

Scheduled for completion in phases beginning in 2026, the investment includes upgrades to reactor systems and supporting infrastructure designed to improve operational flexibility and broaden process capabilities for complex chemistries. Improvements include the installation of an additional cryogenic system to support low-temperature operations across multiple reactors, expanded flow hydrogenation capacity, and continued investment in advanced analytical instrumentation.

Kingchem expects to invest approximately **\$7 million at the Wisconsin site during 2026 alone**. The upgrades include the addition of roughly **1,500 gallons (~5,700 L)** of new Hastelloy reactor capacity as well as **1,000 gallons (~3,800 L)** of new glass-lined capacity. By the end of the year, Kingchem will have invested **more than \$30 million** in the facility since acquiring the site.

Expansion Highlights

- \$7 million investment planned for 2026 facility upgrades
 - More than \$30 million invested since acquiring the Wisconsin campus
 - Addition of approximately 1,500 gallons of Hastelloy reactor capacity
 - Addition of approximately 1,000 gallons of glass-lined reactor capacity
 - Expanded cryogenic processing capability across multiple reactors
 - Increased flow hydrogenation capacity, capable of producing ~1 MT / month
 - New 1,600-square-foot QC / analytical R&D laboratory
 - Expanded instrumentation capacity including ICP-MS and UPLC systems
 - Additional space for stability chambers and QA documentation storage
-



The project also includes bringing into operation a newly acquired and remodeled **1,600-square-foot analytical laboratory** designed to support expanding R&D and quality control capabilities. The new laboratory will house analytical equipment while doubling available bench space for instrumentation and future technology additions. An ICP-MS as well as 3 new GC units have already been purchased. Additional planned investments include UPLC systems, along with nitrogen and hydrogen generator infrastructure to support advanced and safe analytical workflows. The expansion also creates additional space for stability chambers, secure QA document storage, office and conference facilities, and future analytical capabilities.

The Wisconsin campus plays a key role in Kingchem's North American operations, supporting pharmaceutical innovators with services ranging from process development and route scouting through pilot-scale manufacturing and commercial API supply.

"This expansion strengthens Kingchem's ability to support pharmaceutical innovators developing increasingly complex molecules," said **Ryan Yoder, Senior Vice President of Business Development**. "These investments reinforce our commitment to providing sufficient capacity and reliable development and manufacturing solutions while enabling our teams to scale innovative chemistry from early development through commercial production."

The expansion reflects Kingchem's broader strategy to reinforce its position as a **U.S.-founded and controlled CDMO with a growing global platform supporting specialty chemical, pharmaceutical, and biotechnology innovators worldwide.**



www.kingchem.com

+1-201-825-9988

customer-service@kingchem.com

5 Pearl Court, Allendale Park

Allendale, NJ 07401

